Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Account Payables

Amounts the company owes suppliers for goods and services received.

Merck & Co., Inc.NYSE: MRK

Account Payables · Q2 FY2026 · quarter ended Jun 2026

Account payables broadly unchanged from a year ago

Account payables stood at $3.83B at the end of Q2 FY2026, down 1.7% from a year earlier and down 0.9% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Account payables amounted to 2.9% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -1.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.83B-0.9% QoQ
Last fiscal yearDec 2025
$4.4B+8.0% YoY
Year agoJun 2025
$3.89B-1.7% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.7%——
1 year+8.0%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
4.4B USD
Year-over-year change
+8.0%
4-year CAGR
-1.1%

Account Payables vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -1.7% is the 6th highest of 10, against a peer median of +4.2%.
  • Account payables amounts to 2.9% of total assets for MRK, versus a peer median of 4.7%.
MRK Competitors
Account Payables for MRK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABBVAbbVie Inc.Jun 2026$33.17B USD+4.2%+7.0%24.5%
SNYSanofiJun 2026€23.6B EUR+233.5%+2.6%18.3%
AZNAstraZeneca PLCSep 2026$23.53B USD-6.0%+114.8%19.7%
AMGNAmgen Inc.Jun 2026$20.06B USD+566.3%+14.6%21.0%
JNJJohnson & JohnsonSep 2026$9.32B USD-3.2%+6.6%4.7%
LLYEli Lilly and CompanyJun 2026$6.11B USD+50.0%+40.7%4.3%
PFEPfizer Inc.Jun 2026$4.58B USD-11.3%-8.4%2.3%
NVSNovartis AGJun 2026$4.26B USD-5.5%-4.7%3.5%
MRKMerck & Co., Inc.Jun 2026$3.83B USD-1.7%+1.1%2.9%
GILDGilead Sciences, Inc.Jun 2026$674M USD+15.8%-7.6%1.4%
Peer median (excluding MRK) —+4.2%+6.6%4.7%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents8.1B12.69B6.84B13.24B14.57B
Short-term Investments0498M252M447M0
Net Receivables9.23B9.45B10.35B10.28B12.68B
Inventory5.95B5.91B6.36B6.11B6.66B
Other Current Assets6.99B7.17B8.37B8.71B9.49B
Total Current Assets30.27B35.72B32.17B38.78B43.52B
Property, Plant & Equipment (Net)19.28B21.42B23.05B23.78B26.82B
Goodwill21.26B21.2B21.2B21.67B21.58B
Intangible Assets22.93B20.27B18.01B16.37B26.68B
Long-term Investments370M1.02B252M463M2.24B
Tax Assets00000
Other Non-current Assets11.58B9.53B12B16.04B16.03B
Total Non-current Assets75.43B73.44B74.51B78.32B93.35B
Total Assets105.69B109.16B106.68B117.11B136.87B
Account Payables4.61B4.26B3.92B4.08B4.4B
Short-term Debt2.41B1.95B1.37B2.65B2.88B
Tax Payables1.22B1.99B2.65B3.91B0
Deferred Revenue00000
Other Current Liabilities(304M)(281M)(285M)(282M)14.09B
Total Current Liabilities23.87B24.24B25.69B28.42B28.33B
Long-term Debt30.69B28.75B33.68B34.46B46.75B
Deferred Tax Liabilities3.44B1.8B871M1.39B1.44B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities8.21B7.31B7.86B5.59B6.79B
Total Non-current Liabilities43.57B38.86B43.35B42.31B55.88B
Total Liabilities67.44B63.1B69.04B70.73B84.2B
Common Stock1.79B1.79B1.79B1.79B1.79B
Retained Earnings53.7B61.08B53.9B63.07B73.08B
Accumulated OCI(4.43B)(4.77B)(5.16B)(4.95B)(4.29B)
Other Stockholders Equity00000
Minority Interest73M67M54M59M56M
Total Equity38.26B46.06B37.64B46.37B52.66B
Total Debt34.63B31.99B36.27B38.27B50.53B
Net Debt26.54B19.29B29.43B25.03B35.97B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.